Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction

Takahashi,Tsunehiro; Saikawa,Yoshiro; Igarashi,Takahiro; Tsuwano,Shinichi; Kumagai,Koshi; Nakamura,Rieko; Ooyama,Takashi; Wada,Norihito; Takeuchi,Hiroya; Takaishi,Hiromasa; Kitagawa,Yuko

doi:10.3892/ol_00000118

Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction

Authors:
- Tsunehiro Takahashi
- Yoshiro Saikawa
- Takahiro Igarashi
- Shinichi Tsuwano
- Koshi Kumagai
- Rieko Nakamura
- Takashi Ooyama
- Norihito Wada
- Hiroya Takeuchi
- Hiromasa Takaishi
- Yuko Kitagawa
View Affiliations

Affiliations: Keio Cancer Center, Keio University Hospital, Keio University, Tokyo 160-8582, Japan
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000118
Pages: 673-677

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced gastric cancer frequently results in the inability to ingest food or drink orally, a condition called malignant gastrointestinal obstruction (MGO). MGO is clinically defined as a gastrointestinal outlet obstruction caused by a large tumor, or malignant bowel obstruction with peritoneal dissemination. MGO impacts the quality of life by interfering with oral intake and by causing gastrointestinal symptoms, such as nausea, vomiting and abdominal pain. Octreotide acetate (OA) is an analogue of somatostatin which has been increasingly used to relieve gastrointestinal symptoms since it decreases the secretion of digestive juices and increases the absorption of water and electrolytes. In Japan, the oral anticancer drug S-1 was recently adopted as a key chemotherapeutic agent in advanced gastric cancer; however, its oral formulation precludes its utility in the MGO setting. This is a pilot study of chemoradiotherapy plus OA in gastric cancer with MGO. Patients were initially treated with OA to control gastrointestinal symptoms. Following resolution of their symptoms, the patients received chemotherapy with S-1 plus low-dose cisplatin and radiation. Irradiation was targeted at the primary tumor and surrounding lesions, including the lymph nodes. Grade 4 toxicity was observed in only 1 patient, and no treatment-related deaths were noted. After treatment, 3 patients achieved a partial response and 4 achieved stable disease. Of the 9 patients, 8 were able to tolerate solid food orally and were discharged. The outcomes of these cases suggest that OA is a useful adjunctive therapy that enables advanced gastric cancer patients with MGO to receive S-1-containing chemotherapy.

View Figures

View References

1	Mercadante S, Ferrera P, Villari P, et al: Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage. 28:412–416. 2004. View Article : Google Scholar : PubMed/NCBI
2	Dean A: The palliative effects of octreotide in cancer patients. Chemotherapy. 47(Suppl 2): 54–61. 2001. View Article : Google Scholar
3	Khoo D, Hall E, Motson R, et al: Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer. 30A:28–30. 1994. View Article : Google Scholar : PubMed/NCBI
4	Watanabe H, Inoue Y, Uchida K, et al: Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer. J Pediatr Surg. 42:259–260. 2007. View Article : Google Scholar : PubMed/NCBI
5	Shima Y, Ohtsu A, Shirao K, et al: Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 38:354–359. 2008. View Article : Google Scholar : PubMed/NCBI
6	Mercadante S, Spoldi E, Caraceni A, Maddaloni S and Simonetti M: Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 7:295–299. 1993.PubMed/NCBI
7	Marie TF: The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliative Care. 1:20–22. 1994.
8	Sugimachi K, Maehara Y, Horikoshi N, et al: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 57:202–210. 1999. View Article : Google Scholar
9	Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 58:191–197. 2000. View Article : Google Scholar : PubMed/NCBI
10	Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Eng J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
11	Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kumagai K, Saikawa Y, Fukuda K, et al: Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy. Int J Clin Oncol. 14:372–375. 2009. View Article : Google Scholar
13	Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 2nd English edition. Kanehara; Tokyo: 1998
14	Ripamonti C, Twycross R, Baines M, et al: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 9:223–233. 2001. View Article : Google Scholar : PubMed/NCBI
15	Mulvihill SJ, Pappas TN, Fonkalsrud EW and Debas HT: The effect of somatostatin on experimental intestinal obstruction. Ann Surg. 207:169–173. 1998. View Article : Google Scholar : PubMed/NCBI
16	Saikawa Y, Kubota T, Kitajima M, et al: Preoperative combination chemotherapy with S-1 and low-dose cisplatin against highly advanced gastric carcinoma. Oncol Rep. 10:381–386. 2003.PubMed/NCBI
17	Koizumi W, Tanabe S, Saigenji K, et al: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 89:2207–2212. 2003. View Article : Google Scholar : PubMed/NCBI
18	Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
19	Takahashi T, Saikawa Y, Kitajima M, et al: Histological complete response in a case of advanced gastric cancer treated by chemotherapy with S-1 plus low-dose cisplatin and radiation. Jpn J Clin Oncol. 33:584–588. 2003. View Article : Google Scholar : PubMed/NCBI
20	Saikawa Y, Kubota T, Kitajima M, et al: Is chemoradiation effective or harmful for stage IV gastric cancer patients? Oncol Rep. 13:865–870. 2005.PubMed/NCBI
21	Saikawa Y, Kubota T, Kumagai K, et al: Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer. Int J Radiat Oncol Biol Phys. 71:173–179. 2008. View Article : Google Scholar : PubMed/NCBI